173 related articles for article (PubMed ID: 12164939)
41. Oral treatment of keratinizing disorders of skin and mucous membranes with etretinate. Comparative study of 113 patients.
Mahrle G; Meyer-Hamme S; Ippen H
Arch Dermatol; 1982 Feb; 118(2):97-100. PubMed ID: 7059226
[TBL] [Abstract][Full Text] [Related]
42. An open trial of topical urocanic acid for the treatment of stable plaque psoriasis.
Vestey JP; Norval M
Photodermatol Photoimmunol Photomed; 1997; 13(1-2):67-8. PubMed ID: 9361132
[No Abstract] [Full Text] [Related]
43. Effects of [D-Ala1] peptide T-NH2 and HIV envelope glycoprotein gp120 on cyclic AMP dependent protein kinases in normal and psoriatic human fibroblasts.
Liapi C; Takahashi N; Raynaud F; Evain-Brion D; Anderson WB
J Invest Dermatol; 1998 Apr; 110(4):332-7. PubMed ID: 9540970
[TBL] [Abstract][Full Text] [Related]
44. Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis.
Baran A; Świderska M; Bacharewicz-Szczerbicka J; Myśliwiec H; Flisiak I
Lipids; 2017 Jan; 52(1):51-60. PubMed ID: 27864793
[TBL] [Abstract][Full Text] [Related]
45. The treatment of psoriasis with etretinate and acitretin: a follow up of actual use.
Magis NL; Blummel JJ; Kerkhof PC; Gerritsen RM
Eur J Dermatol; 2000; 10(7):517-21. PubMed ID: 11056421
[TBL] [Abstract][Full Text] [Related]
46. [Reader's letter on Norbert Haas, Andrea Wulff-Woesten,W. Sterry and H. Meffert. The treatment of psoriasis capillitii with dithranol. JDDG 2003, 1:688-693].
Ummenhofer B
J Dtsch Dermatol Ges; 2003 Dec; 1(12):1002-3; author reply 1003. PubMed ID: 16285653
[No Abstract] [Full Text] [Related]
47. Sequential therapy using cyclosporine and acitretin for treatment of total body psoriasis.
Short MW; Vaughan TK
Cutis; 2004 Sep; 74(3):185-8. PubMed ID: 15499760
[TBL] [Abstract][Full Text] [Related]
48. Crystal structures of RIalpha subunit of cyclic adenosine 5'-monophosphate (cAMP)-dependent protein kinase complexed with (Rp)-adenosine 3',5'-cyclic monophosphothioate and (Sp)-adenosine 3',5'-cyclic monophosphothioate, the phosphothioate analogues of cAMP.
Wu J; Jones JM; Nguyen-Huu X; Ten Eyck LF; Taylor SS
Biochemistry; 2004 Jun; 43(21):6620-9. PubMed ID: 15157095
[TBL] [Abstract][Full Text] [Related]
49. Calmodulin inhibition by anthralin? Investigations in vitro and in vivo.
Wollina U; Klinger R; Wetzker R; Knopf B
Dermatologica; 1989; 179(2):61-3. PubMed ID: 2529149
[TBL] [Abstract][Full Text] [Related]
50. Topical anthralin for psoriasis vulgaris: evaluation of 70 Japanese patients.
Yamamoto T; Matsuuchi M; Irimajiri J; Otoyama K; Nishioka K
J Dermatol; 2000 Jul; 27(7):482-5. PubMed ID: 10935350
[TBL] [Abstract][Full Text] [Related]
51. Chronic plaque psoriasis.
Naldi L; Rzany B
Clin Evid; 2005 Jun; (13):2070-98. PubMed ID: 16135323
[No Abstract] [Full Text] [Related]
52. [Effect of etretinate treatment on fluidity and lipid composition of the erythrocyte membrane in patients with psoriasis].
Simonetti O; Messini L
G Ital Dermatol Venereol; 1989; 124(11-12):493-7. PubMed ID: 2638642
[TBL] [Abstract][Full Text] [Related]
53. Acitretin for the treatment of psoriasis: an assessment of national trends.
Ghasri P; Yentzer BA; Dabade TS; Feldman SR
J Drugs Dermatol; 2011 Aug; 10(8):873-7. PubMed ID: 21818508
[TBL] [Abstract][Full Text] [Related]
54. Advances in psoriasis treatment.
Feldman S
Dermatol Online J; 2000 Sep; 6(1):4. PubMed ID: 11328614
[TBL] [Abstract][Full Text] [Related]
55. [The immunology of psoriasis: from basic research to the bedside].
Gyulai R; Kemény L
Orv Hetil; 2006 Nov; 147(46):2213-20. PubMed ID: 17396393
[TBL] [Abstract][Full Text] [Related]
56. Topical therapy for psoriasis.
Lebwohl M; Abel E; Zanolli M; Koo J; Drake L
Int J Dermatol; 1995 Oct; 34(10):673-84. PubMed ID: 8537153
[No Abstract] [Full Text] [Related]
57. Acitretin.
Ortiz NE; Nijhawan RI; Weinberg JM
Dermatol Ther; 2013; 26(5):390-9. PubMed ID: 24099069
[TBL] [Abstract][Full Text] [Related]
58. Effects of antipsoriatic therapies on hepatic microsomal enzyme activity in patients with psoriasis.
Brockmeyer NH; Frühauf S; Mertins L; Barthel B; Goos M
Eur J Med Res; 1998 Aug; 3(8):361-6. PubMed ID: 9707517
[TBL] [Abstract][Full Text] [Related]
59. Sex-specific differences in the treatment of severe psoriasis.
Hotard RS; Feldman SR; Fleischer AB
J Am Acad Dermatol; 2000 Apr; 42(4):620-3. PubMed ID: 10727307
[TBL] [Abstract][Full Text] [Related]
60. Increased insulin-like growth factor binding protein-3 expression level in psoriatic tissue before and after systemic treatment with cyclosporine A and methotrexate.
Ozden MG; Ilter N; Suer OE; Solaktekin N; Gürer MA
Int J Dermatol; 2008 Nov; 47(11):1177-83. PubMed ID: 18986456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
